Inclusion Conjunctivitis disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: INC003 MIFTS: 42	Inclusion Conjunctivitis Categories: Eye diseases, Infectious diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Inclusion Conjunctivitis

MalaCards integrated aliases for Inclusion Conjunctivitis:

Name: Inclusion Conjunctivitis ¹² ⁷⁶ ⁵³ ¹⁵ ⁷³

Inclusion Conjunctivitis of the Adult ⁷³

Neonatal Chlamydial Conjunctivitis ⁷³

Adult Inclusion Conjunctivitis ¹²

Chlamydial Conjunctivitis ¹²

Conjunctivitis, Inclusion ⁴⁴

Inclusion Blennorrhoea ¹²

Inclusion Blenorrhea ¹²

Paratrachoma ¹²

Classifications:

MalaCards categories:
Global: Rare diseases Infectious diseases
Anatomical: Eye diseases

See all MalaCards categories (disease lists)

ICD10: ³³

Certain infectious and parasitic diseases

Other diseases caused by chlamydiae

Chlamydial conjunctivitis

External Ids:

Disease Ontology ¹² DOID:13800

ICD10 ³³ A74.0

ICD9CM ³⁵ 077.0

MeSH ⁴⁴ D003235

SNOMED-CT ⁶⁸ 56009001

UMLS ⁷³ C0009770 C0343723 C0392644

Sources

Summaries for Inclusion Conjunctivitis

Disease Ontology : ¹² A commensal bacterial infectious disease that results in inflammation, located in conjunctiva of the eye, has material basis in Chlamydia trachomatis, which is transmitted by sexual contact. The infection has symptom swollen conjunctiva and eyelids and has symptom discharge of pus and mucus.

MalaCards based summary : Inclusion Conjunctivitis, also known as inclusion conjunctivitis of the adult, is related to salpingitis and conjunctivitis, and has symptoms including swollen conjunctiva and discharge of pus. An important gene associated with Inclusion Conjunctivitis is WDR13 (WD Repeat Domain 13), and among its related pathways/superpathways are Lung fibrosis and G-protein signaling_RhoB regulation pathway. The drugs Azithromycin and Permethrin have been mentioned in the context of this disorder. Affiliated tissues include eye, testes and lung.

Wikipedia : ⁷⁶ Conjunctivitis, also known as pink eye, is inflammation of the outermost layer of the white part of the... more...

Sources

Related Diseases for Inclusion Conjunctivitis

Diseases related to Inclusion Conjunctivitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 53)

#	Related Disease	Score	Top Affiliating Genes
1	salpingitis	30.1	OVGP1 TNF
2	conjunctivitis	10.8
3	trachoma	10.6
4	chlamydia	10.4
5	acute conjunctivitis	10.3	PLD3 PSEN2
6	acute hemorrhagic conjunctivitis	10.3	PLD3 PSEN2
7	whiplash	10.2	CCL5 IL16
8	scorpion envenomation	10.2	CCL5 TNF
9	staphylococcal toxic shock syndrome	10.2	HMGB1 TNF
10	angioimmunoblastic lymphadenopathy with dysproteinemia	10.2	IL5 TNF
11	iritis	10.2	MRAP PSEN2
12	respiratory syncytial virus infectious disease	10.2	CCL5 IL5
13	posterior scleritis	10.2	MRAP TNF
14	scleritis	10.2	IL5 TNF
15	juvenile ankylosing spondylitis	10.2	MRAP TNF
16	scleral disease	10.2	MRAP TNF
17	pustulosis of palm and sole	10.2	MRAP TNF
18	anca-associated vasculitis	10.2	HMGB1 TNF
19	whipple disease	10.1	IL16 MRAP
20	cow milk allergy	10.1	IL5 TNF
21	acute salpingitis	10.1	MRAP OVGP1 TNF
22	allergic asthma	10.1	CCL5 IL16 IL5
23	idiopathic neutropenia	10.1	CCL5 HMGB1 TNF
24	cardiac sarcoidosis	10.1	IL5 TNF
25	churg-strauss syndrome	10.1	HMGB1 IL5 TNF
26	melancholia	10.1	TF TNF
27	filariasis	10.1	CCL5 IL5 TNF
28	upper respiratory tract disease	10.1	CCL5 IL5 TNF
29	bronchial disease	10.1	CCL5 IL5 TNF
30	macrophage activation syndrome	10.1	HMGB1 TNF
31	bronchiolitis	10.1	CCL5 IL5 TNF
32	proteasome-associated autoinflammatory syndrome 1	10.1	CCL5 IL5 TNF
33	shipyard eye	10.1	PLD3 PSEN2
34	trichosporonosis	10.1	TNF TXN
35	cerebral artery occlusion	10.1	IL16 TNF
36	respiratory system disease	10.1	CCL5 IL5 TNF
37	haemophilus influenzae	10.1	TF TNF
38	trypanosomiasis	10.1	CCL5 TF TNF
39	interstitial lung disease	10.0	CCL5 TF TNF
40	lymphogranuloma venereum	10.0
41	ornithosis	10.0
42	urethritis	10.0
43	pneumonia	10.0	CCL5 IL5 TNF
44	dermatitis, atopic	10.0	CCL5 IL16 IL5 TNF
45	arthritis	9.9
46	uveitis	9.9
47	cellulitis	9.9
48	reactive arthritis	9.9
49	conjunctival disease	9.9	IL5 MRAP PLD3 PSEN2 TNF
50	radiation proctitis	9.9	TF TNF

Graphical network of the top 20 diseases related to Inclusion Conjunctivitis:

Sources

Symptoms & Phenotypes for Inclusion Conjunctivitis

Symptoms:

¹²

• swollen conjunctiva

• discharge of pus

Sources

Drugs & Therapeutics for Inclusion Conjunctivitis

Drugs for Inclusion Conjunctivitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 34)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Azithromycin

Approved

Phase 4,Phase 3,Phase 2,Not Applicable

83905-01-5

55185 447043

Permethrin

Approved, Investigational

Phase 4

52645-53-1

40326

Tetracycline

Approved, Vet_approved

Phase 4

60-54-8

5353990

Albendazole

Approved, Vet_approved

Phase 4,Phase 3,Not Applicable

54965-21-8

2082

Ivermectin

Approved, Investigational, Vet_approved

Phase 4,Phase 3,Not Applicable

70288-86-7

6474909

Trimethoprim

Approved, Vet_approved

Phase 4

738-70-5

5578

Amoxicillin

Approved, Vet_approved

Phase 4

26787-78-0

33613

Sulfamethoxazole

Approved

Phase 4

723-46-6

5329

Anti-Infective Agents

Phase 4,Phase 3,Not Applicable

Anti-Bacterial Agents

Phase 4,Phase 3,Phase 2,Not Applicable

Antibiotics, Antitubercular

Phase 4,Phase 2,Phase 3

Antiprotozoal Agents

Phase 4,Phase 3,Not Applicable

Antiparasitic Agents

Phase 4,Phase 3,Not Applicable

Antimitotic Agents

Phase 4,Phase 3,Not Applicable

Anthelmintics

Phase 4,Phase 3,Not Applicable

Antitubercular Agents

Phase 4

Renal Agents

Phase 4

Anti-Infective Agents, Urinary

Phase 4

Antimalarials

Phase 4

Trimethoprim, Sulfamethoxazole Drug Combination

Phase 4

Immunologic Factors

Phase 4

Vaccines

Phase 4

Diethylcarbamazine

Approved, Investigational, Vet_approved

Phase 3

90-89-1

3052

Ophthalmic Solutions

Phase 3,Not Applicable

Pharmaceutical Solutions

Phase 3,Not Applicable

Lipoxygenase Inhibitors

Phase 3

Fluorometholone

Approved, Investigational

Not Applicable

426-13-1

9878

Lubricant Eye Drops

Not Applicable

Anti-Inflammatory Agents

Not Applicable

Anti-Allergic Agents

Not Applicable

Hormones, Hormone Substitutes, and Hormone Antagonists

Not Applicable

Hormones

Not Applicable

glucocorticoids

Not Applicable

Hormone Antagonists

Not Applicable

Interventional clinical trials:

(show all 38)

#	Name	Status	NCT ID	Phase	Drugs
1	Partnership for Rapid Elimination of Trachoma	Completed	NCT00792922	Phase 4	Azithromycin;Azithromycin
2	Effect of Intensive Fly Control on Trachoma and Ocular Chlamydia Infection in Tanzania	Completed	NCT00347763	Phase 4
3	Study of Three Alternatives for Mass Treatment in Trachoma Villages of Tanzania	Completed	NCT00347607	Phase 4
4	Impact of Water and Health Education Programs on Trachoma and Ocular C. Trachomatis in Niger	Completed	NCT00348478	Phase 4
5	Impact of Two Alternative Dosing Strategies for Trachoma Control in Niger	Completed	NCT00618449	Phase 4	Azithromcyin;Azithromycin
6	Trachoma Elimination Follow-up	Completed	NCT00221364	Phase 4	Mass treatment with oral azithromycin to an entire village
7	Trachoma Amelioration in Northern Amhara (TANA)	Completed	NCT00322972	Phase 4	Mass treatment with oral azithromycin to an entire community
8	Tripartite International Research for the Elimination of Trachoma	Completed	NCT01202331	Phase 4	mass treatment with oral azithromycin
9	A Trial of Non-absorbable Versus Absorbable Sutures for Trichiasis Surgery	Completed	NCT00522860	Phase 4
10	Study of Azithromycin to Prevent Recurrent Trichiasis Following Surgery in Ethiopia	Completed	NCT00347776	Phase 4	azithromycin;topical tetracycline
11	Mortality Reduction After Oral Azithromycin: Mortality Study	Completed	NCT02047981	Phase 4	Azithromycin;Placebo
12	Sanitation, Water, and Instruction in Face-washing for Trachoma	Recruiting	NCT02754583	Phase 4	Azithromycin;Tetracycline;Albendazole
13	Azithromycin to Prevent Post-discharge Morbidity and Mortality in Kenyan Children	Recruiting	NCT02414399	Phase 4	Azithromycin;Placebo
14	Antibiotic Resistance and Microbiome in Children Aged 6-59 Months in Nouna, Burkina Faso	Active, not recruiting	NCT03187834	Phase 4	Azithromycin;Amoxicillin;Cotrimoxazole;Placebo
15	Mortality Reduction After Oral Azithromycin: Morbidity Study	Enrolling by invitation	NCT02048007	Phase 4	Azithromycin;Placebo
16	Trachoma Elimination Study by Focused Antibiotic (TESFA)	Not yet recruiting	NCT03523156	Phase 4	Azithromycin mass treatment;Azithromycin targeted treatment
17	Kebele Elimination of Trachoma for Ocular Health	Not yet recruiting	NCT03335072	Phase 4	Azithromycin
18	Cluster RCT of Co-administration Azithromycin, Albendazole & Ivermectin	Not yet recruiting	NCT03570814	Phase 4	Administration of Albendazole on Day 1;Administration of Ivermectin on Day 1;Administration of Azithromycin on Day 1;Administration of Azithromycin on Day 15
19	MORDOR II Burkina Faso Community	Not yet recruiting	NCT03676764	Phase 4	Azithromycin;Placebos
20	Azithromycin in Control of Trachoma II	Withdrawn	NCT00286026	Phase 4	Azithromycin
21	Safety Study of Combined Azithromycin, Ivermectin and Albendazole for Trachoma and Lymphatic Filariasis	Withdrawn	NCT01903057	Phase 4	azithromycin;ivermectin;albendazole;placebo
22	Efficacy and Safety of 2 Dosing Regimens of T1225 Eye Drops 1.5% Versus Oral Azithromycin in Treatment of Trachoma	Completed	NCT00356720	Phase 3	Azithromycin
23	Prevention of Bacterial Infections in Newborn	Completed	NCT01800942	Phase 3	Azithromycin and Placebo
24	Pre-delivery Administration of Azithromycin to Prevent Neonatal Sepsis & Death	Recruiting	NCT03199547	Phase 3	Azithromycin;Placebo Oral Tablet
25	Safety of Co-administration of IDA and Azithromycin for NTDs ( ComboNTDs )	Not yet recruiting	NCT03676140	Phase 3	Albendazole on Day 1;Ivermectin on Day 1;Diethylcarbamazine on day 1;Azithromycin on Day 1;Azithromycin on Day 8
26	Nepal Elimination of Trachoma Study	Withdrawn	NCT02176057	Phase 2, Phase 3	Azithromycin
27	Testing Insect Repellents Against Musca Sorbens, the Vector of Trachoma	Recruiting	NCT03813069	Phase 2
28	The Effect of Oral Azithromycin in the Treatment of Chlamydial Conjunctivitis	Completed	NCT01178762	Not Applicable	Azithromycin
29	A Surveillance and Azithromycin Treatment for Newcomers and Travelers Evaluation: The ASANTE Trial	Completed	NCT01767506	Not Applicable
30	Modified Instrumentation for Surgery to Correct Trichiasis	Completed	NCT00886015	Not Applicable
31	Water Uptake for Health in Amhara Pilot	Completed	NCT02373657	Not Applicable
32	Safety of the Co-administration of Three Drugs for Trachoma and Lymphatic Filariasis Elimination	Completed	NCT01586169	Not Applicable	triple co administration at once of the combination of Albendazole + ivermectin + azithromycin
33	Identification of TT Cases by Community Treatment Assistants: An Assessment	Completed	NCT01783743	Not Applicable
34	Fluorometholone as Ancillary Therapy for TT Surgery	Completed	NCT01949454	Not Applicable	Fluorometholone 0.1% ophthalmic solution
35	The Effect of Long-Term HEAD START Training on Surgical Skill Levels	Completed	NCT03135080	Not Applicable
36	A Trial of Epilation Verses Surgery for Minor Trichiasis	Completed	NCT00522912	Not Applicable
37	Comparison of Ultrasonic Pachymetry With Orbscan in Corneal Haze	Completed	NCT00439114
38	Performance of a Photoscreener for Vision Screening in a Haitian Pediatric Population	Withdrawn	NCT02655432

Search NIH Clinical Center for Inclusion Conjunctivitis

Cochrane evidence based reviews: conjunctivitis, inclusion

Sources

Genetic Tests for Inclusion Conjunctivitis

Sources

Anatomical Context for Inclusion Conjunctivitis

MalaCards organs/tissues related to Inclusion Conjunctivitis:

⁴¹

Eye, Testes, Lung

The Foundational Model of Anatomy Ontology organs/tissues related to Inclusion Conjunctivitis:

¹⁹

Conjunctiva Of The Eye

Sources

Publications for Inclusion Conjunctivitis

Articles related to Inclusion Conjunctivitis:

(show top 50) (show all 111)

#	Title	Authors	Year
1	Conjunctival infection with Chlamydia trachomatis in sexual partners of patients with adult inclusion conjunctivitis. ( 24643518 )	Mohamed-Noriega K....Mohamed-Hamsho J.	2014
2	Evaluation of single-dose azithromycin versus standard azithromycin/doxycycline treatment and clinical assessment of regression course in patients with adult inclusion conjunctivitis. ( 24047438 )		2013
3	Evaluation of direct immunofluorescence assay and cytological examination in comparison to polymerase chain reaction of conjunctival swabs in patients with adult inclusion conjunctivitis. ( 23627371 )		2013
4	Effect of inflammatory response on in vivo competition between two chlamydial variants in the guinea pig model of inclusion conjunctivitis. ( 22144478 )		2012
5	Combination of adult inclusion conjunctivitis and mucosa-associated lymphoid tissue (MALT) lymphoma in a young adult. ( 14701961 )	Yeung L....Lai L.J.	2004
6	Azithromycin vs doxycycline in the treatment of inclusion conjunctivitis. ( 12654359 )	Katusic D....Petricek G.	2003
7	Phage infection of the obligate intracellular bacterium, Chlamydia psittaci strain guinea pig inclusion conjunctivitis. ( 10955956 )	Hsia R....Bavoil P.M.	2000
8	Microvirus of chlamydia psittaci strain guinea pig inclusion conjunctivitis: isolation and molecular characterization. ( 10878129 )		2000
9	Homologs of Escherichia coli recJ, gltX and of a putative 'early' gene of avian Chlamydia psittaci are located upstream of the 'late' omp2 locus of Chlamydia psittaci strain guinea pig inclusion conjunctivitis. ( 8918248 )	Hsia R.C....Bavoil P.M.	1996
10	Serotyping of Chlamydia trachomatis from inclusion conjunctivitis by polymerase chain reaction and restriction fragment length polymorphism analysis. ( 8876399 )	Isobe K....Hashimoto N.	1996
11	Immunity to reinfection and immunization of male guinea pigs against urethral infection with the agent of guinea pig inclusion conjunctivitis. ( 8919742 )		1996
12	Evaluation of the Kodak Surecell Chlamydia test for the laboratory diagnosis of adult inclusion conjunctivitis. ( 9121749 )	Tantisira J.G....Gordon Y.J.	1995
13	Increased incidence of oviduct pathology in the guinea pig after repeat vaginal inoculation with the chlamydial agent of guinea pig inclusion conjunctivitis. ( 7709325 )		1995
14	Dissociation of immune determinants of outer membrane proteins of Chlamydia psittaci strain guinea pig inclusion conjunctivitis. ( 7525489 )	Westbay T.D....Zauderer M.	1994
15	Diagnosing inclusion conjunctivitis. ( 7852700 )		1994
16	Partial protection against genital reinfection by immunization of guinea-pigs with isolated outer-membrane proteins of the chlamydial agent of guinea-pig inclusion conjunctivitis. ( 7510322 )	Batteiger B.E....Soderberg L.S.	1993
17	Lack of allelic polymorphism for the major outer membrane protein gene of the agent of guinea pig inclusion conjunctivitis (Chlamydia psittaci). ( 8514416 )	Zhao Q....Stephens R.S.	1993
18	Monoclonal antibodies to Chlamydia psittaci guinea pig inclusion conjunctivitis (GPIC) strain. ( 2186565 )	Cherian P.V....Magee W.E.	1990
19	Role of cell-mediated immunity in the resolution of secondary chlamydial genital infection in guinea pigs infected with the agent of guinea pig inclusion conjunctivitis. ( 2917782 )	Rank R.G....Batteiger B.E.	1989
20	Ultrastructural studies on the intracellular fate of Chlamydia psittaci (strain guinea pig inclusion conjunctivitis) and Chlamydia trachomatis (strain lymphogranuloma venereum 434): modulation of intracellular events and relationship with endocytic mechanism. ( 2614396 )	Prain C.J....Pearce J.H.	1989
21	Guineapig inclusion conjunctivitis (GPIC) in a commercial colony. ( 2651796 )	Deeb B.J....Wang S.P.	1989
22	Persistence of inclusion conjunctivitis after oral erythromycin therapy. ( 3179892 )	LaperriA"re H....Lefebvre J.	1988
23	Regulation of Chlamydia psittaci (strain guinea pig inclusion conjunctivitis) growth in McCoy cells by amino acid antagonism. ( 3655729 )		1987
24	Electron microscopic observations concerning the in vivo uptake and release of the agent of guinea-pig inclusion conjunctivitis (Chlamydia psittaci) in guinea-pig exocervix. ( 4031129 )	Soloff B.L....Barron A.L.	1985
25	A study of inclusion conjunctivitis in newborn and young adults. Clinical picture, culture, conjunctival scrapings and cytology of the tear fluid in 12 cases. ( 6362323 )	MA...Kaern J.	1983
26	Differential amino acid utilization by Chlamydia psittaci (strain guinea pig inclusion conjunctivitis) and its regulatory effect on chlamydial growth. ( 6415225 )	Allan I....Pearce J.H.	1983
27	Chlamydial inclusion conjunctivitis of the newborn. ( 6834172 )		1983
28	Serum and tear antibodies to Chlamydia after reinfection with guinea pig inclusion conjunctivitis agent. ( 7031009 )	Malaty R....Schachter J.	1981
29	'Innocent' neonatal inclusion conjunctivitis: parental origins and complications. ( 21289694 )	Houck L.V....Embil J.A.	1981
30	Cell-mediated and humoral immune responses to chlamydial antigens in guinea pigs infected ocularly with the agent of guinea pig inclusion conjunctivitis. ( 7012031 )	Senyk G....Jawetz E.	1981
31	Adult inclusion conjunctivitis. Clinical characteristics and corneal changes. ( 7224930 )		1981
32	Ocular and dermal delayed hypersensitivity reactions in guinea-pigs following infection with guinea-pig inclusion conjunctivitis agent (Chlamydia psittaci). ( 7261478 )		1981
33	Guinea-pig inclusion conjunctivitis as a model for the study of trachoma: clinical, microbiological, serological, and cytological studies of primary infection. ( 7387961 )	Monnickendam M.A....Tilbury A.M.	1980
34	Target tissues associated with genital infection of female guinea pigs by the chlamydial agent of guinea pig inclusion conjunctivitis. ( 374637 )		1979
35	Experimental chlamydial salpingitis in immunosuppressed guinea pigs infected in the genital tract with the agent of guinea pig inclusion conjunctivitis. ( 397933 )		1979
36	Humoral immunity in the resolution of genital infection in female guinea pigs infected with the agent of guinea pig inclusion conjunctivitis. ( 546788 )	Rank RG...Barron AL	1979
37	Immunity to vaginal reinfection in female guinea pigs infected sexually with Chlamydia of guinea pig inclusion conjunctivitis. ( 640729 )	Lamont H.C....Nichols R.L.	1978
38	Staphylococcal infection superimposed on guinea pig inclusion conjunctivitis. ( 638844 )	Howcroft MJ...Schachter J	1978
39	Resistance to reinfection with a chlamydial agent (guinea pig inclusion conjunctivitis agent). ( 863616 )	Ahmad A....Schachter J.	1977
40	Limited survey of genital infection by guinea pig inclusion conjunctivitis agent. ( 921034 )		1977
41	Severe persistent inclusion conjunctivitis in a young child. ( 848548 )		1977
42	Infectivity titration of guinea-pig inclusion conjunctivitis agent in irradiated McCoy cells. ( 986419 )	Griffiths M.S....Pearce J.H.	1976
43	Intrarectal infection of guinea pigs with the agent of guinea pig inclusion conjunctivitis. ( 1013148 )	Mount D.T....Barron A.L.	1976
44	Animal model studies of genital chlamydial infections. Immunity to re-infection with guinea-pig inclusion conjunctivitis agent in the urethra and eye of male guinea-pigs. ( 963491 )	Howard L.V....Nichols R.L.	1976
45	Ultrastructural study of trachoma and inclusion conjunctivitis. ( 1028127 )	Verin P....Vildy A.	1976
46	The effect of cyclophosphamide on the recovery from a local chlamydial infection. Guinea-pig inclusion conjunctivitis (GPIC). ( 1088418 )		1976
47	Three new immunologic types of trachoma-inclusion conjunctivitis organisms. ( 4631875 )	Wang S.P....Gale J.L.	1973
48	Immunity to chlamydial infections of the eye. II. Studies of passively transferred serum antibody in resistance to infection with guinea pig inclusion conjunctivitis. ( 4586860 )	Watson R.R....Bear S.E.	1973
49	A simplified method for immunological typing of trachoma-inclusion conjunctivitis-lymphogranuloma venereum organisms. ( 16558075 )	Wang S.P....GRAYSTON J.T.	1973
50	Isolation and identification of trachoma and inclusion conjunctivitis agents in Melbourne, 1966 to 1972. ( 4351871 )		1973

Sources

Genes for Inclusion Conjunctivitis

Genes related to Inclusion Conjunctivitis (0 elite genes):

(show all 19)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	WDR13	WD Repeat Domain 13	Protein Coding	16.35	DISEASES inferred ¹⁵
2	OVGP1	Oviductal Glycoprotein 1	Protein Coding	15.82	DISEASES inferred ¹⁵
3	PLD3	Phospholipase D Family Member 3	Protein Coding	15.68	DISEASES inferred ¹⁵
4	GPR132	G Protein-Coupled Receptor 132	Protein Coding	14.92	DISEASES inferred ¹⁵
5	IL16	Interleukin 16	Protein Coding	14.72	DISEASES inferred ¹⁵
6	CTTNBP2	Cortactin Binding Protein 2	Protein Coding	14.5	DISEASES inferred ¹⁵
7	PSEN2	Presenilin 2	Protein Coding	14.26	DISEASES inferred ¹⁵
8	HMGB1	High Mobility Group Box 1	Protein Coding	13.8	DISEASES inferred ¹⁵
9	CCL5	C-C Motif Chemokine Ligand 5	Protein Coding	13.74	DISEASES inferred ¹⁵
10	MRAP	Melanocortin 2 Receptor Accessory Protein	Protein Coding	13.32	DISEASES inferred ¹⁵
11	IL5	Interleukin 5	Protein Coding	13.22	DISEASES inferred ¹⁵
12	TNF	Tumor Necrosis Factor	Protein Coding	13.16	DISEASES inferred ¹⁵
13	TF	Transferrin	Protein Coding	13	DISEASES inferred ¹⁵
14	ANXA5	Annexin A5	Protein Coding	12.95	DISEASES inferred ¹⁵
15	TXLNA	Taxilin Alpha	Protein Coding	6.4	DISEASES inferred ¹⁵
16	TMBIM6	Transmembrane BAX Inhibitor Motif Containing 6	Protein Coding	5.6	DISEASES inferred ¹⁵
17	CKAP2	Cytoskeleton Associated Protein 2	Protein Coding	5.51	DISEASES inferred ¹⁵
18	OXA1L	OXA1L, Mitochondrial Inner Membrane Protein	Protein Coding	5.05	DISEASES inferred ¹⁵
19	TXN	Thioredoxin	Protein Coding	4.03	DISEASES inferred ¹⁵

Sources

Variations for Inclusion Conjunctivitis

Sources

Expression for Inclusion Conjunctivitis

Search GEO for disease gene expression data for Inclusion Conjunctivitis.

Sources

Pathways for Inclusion Conjunctivitis

Pathways related to Inclusion Conjunctivitis according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Lung fibrosis ¹	10.93	CCL5 IL5 TNF
2	G-protein signaling_RhoB regulation pathway ²²	10.15	CCL5 IL16 IL5 TNF

Sources

GO Terms for Inclusion Conjunctivitis

Cellular components related to Inclusion Conjunctivitis according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular region	GO:0005576	9.32	ANXA5 CCL5 HMGB1 IL16 IL5 OVGP1

Biological processes related to Inclusion Conjunctivitis according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	cytokine-mediated signaling pathway	GO:0019221	9.35	CCL5 IL16 IL5 TNF TXLNA
2	positive regulation of monocyte chemotaxis	GO:0090026	9.32	CCL5 HMGB1
3	dendritic cell chemotaxis	GO:0002407	9.26	CCL5 HMGB1
4	positive regulation of podosome assembly	GO:0071803	9.16	IL5 TNF
5	regulation of signaling receptor activity	GO:0010469	9.1	CCL5 HMGB1 IL16 IL5 TNF TXLNA

Molecular functions related to Inclusion Conjunctivitis according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	cytokine activity	GO:0005125	9.1	CCL5 HMGB1 IL16 IL5 TNF TXLNA

Sources

Sources for Inclusion Conjunctivitis

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia